相似文献
1
Safety of alternate-day treatment with TS-1 (tegafur/gimeracil/oteracil) in tumor-bearing dogs: a pilot study.
J Vet Med Sci. 2021 Aug 6;83(8):1206-1211. doi: 10.1292/jvms.21-0060. Epub 2021 Jun 18.
2
Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Prescrire Int. 2013 May;22(138):122.
3
The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma.
Cell Biochem Biophys. 2015 Jul;72(3):695-9. doi: 10.1007/s12013-015-0520-0.
4
Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Int J Clin Oncol. 2004 Jun;9(3):143-8. doi: 10.1007/s10147-004-0381-9.
5
Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Drug Metab Pharmacokinet. 2007 Jun;22(3):162-8. doi: 10.2133/dmpk.22.162.
6
Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.
Molecules. 2017 Sep 7;22(9):1488. doi: 10.3390/molecules22091488.
7
Efficacy and safety of S-1 (tegafur, gimeracil, and oteracil potassium) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients.
Cancer Radiother. 2016 May;20(3):181-6. doi: 10.1016/j.canrad.2015.12.004. Epub 2016 Apr 7.
8
Preclinical/clinical trials of thrice-weekly administration of a combination of tegafur/gimeracil/oteracil (TS-1) and toceranib phosphate in dogs with intranasal tumors.
J Vet Med Sci. 2024 Nov 1;86(11):1129-1135. doi: 10.1292/jvms.23-0455. Epub 2024 Oct 3.
9
The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium.
Cancer Chemother Pharmacol. 2008 Aug;62(3):427-32. doi: 10.1007/s00280-007-0621-6. Epub 2007 Nov 17.
10
[Tegafur/gimeracil/oteracil (Teysuno), by oral administration].
J Pharm Belg. 2013 Dec(4):35-6.
引用本文的文献
1
Preclinical/clinical trials of thrice-weekly administration of a combination of tegafur/gimeracil/oteracil (TS-1) and toceranib phosphate in dogs with intranasal tumors.
J Vet Med Sci. 2024 Nov 1;86(11):1129-1135. doi: 10.1292/jvms.23-0455. Epub 2024 Oct 3.
本文引用的文献
1
Intraoperative acridine orange photodynamic therapy and cribriform electron-beam irradiation for canine intranasal carcinomas: 14 cases.
Can Vet J. 2019 May;60(5):509-513.
2
Concurrent 5-fluorouracil and carboplatin for the treatment of canine carcinomas.
Vet Comp Oncol. 2018 Dec;16(4):590-595. doi: 10.1111/vco.12426. Epub 2018 Jul 24.
3
A dog's life: an unfamiliar and lethal side effect of topical 5-fluorouracil.
Clin Exp Dermatol. 2018 Aug;43(6):732. doi: 10.1111/ced.13537. Epub 2018 Jun 11.
4
Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1.
Vet Comp Oncol. 2016 Dec;14(4):417-446. doi: 10.1111/vco.283.
5
Alleviating effects of artificial tear instillation on S-1-induced ocular toxicity in dogs.
J Toxicol Sci. 2017;42(3):291-300. doi: 10.2131/jts.42.291.
6
New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin.
Chemotherapy. 2017;62(1):62-70. doi: 10.1159/000443984. Epub 2016 Sep 20.
7
Conduct, Oversight, and Ethical Considerations of Clinical Trials in Companion Animals with Cancer: Report of a Workshop on Best Practice Recommendations.
J Vet Intern Med. 2016 Mar-Apr;30(2):527-35. doi: 10.1111/jvim.13916. Epub 2016 Mar 7.
8
9
Treatment of corneal squamous cell carcinoma using topical 1% 5-fluorouracil as monotherapy.
Vet Ophthalmol. 2016 May;19(3):256-261. doi: 10.1111/vop.12290. Epub 2015 Jun 15.
10
A pulse-dose topical 1% 5-fluorouracil treatment regimen in a young dog with corneal squamous cell carcinoma.
Vet Ophthalmol. 2015 Jul;18(4):350-4. doi: 10.1111/vop.12220. Epub 2014 Oct 1.
Zotero 插件
